Prelude Therapeutics Unveils Abstracts for EORTC-NCI-AACR Symposium
Prelude Therapeutics Incorporated (Nasdaq: PRLD) has exciting news to share with the scientific community. The company announced the publication of three important abstracts related to its innovative SMARCA Degrader Programs. These abstracts will be featured at the 36th EORTC-NCI-AACR Symposium, an esteemed event in the world of oncology research.
Overview of the Upcoming Symposium
The symposium is scheduled to take place in Barcelona, where experts and researchers will gather to discuss cutting-edge developments in cancer treatments from October 23 to 25. Prelude is particularly eager to present valuable insights from its clinical and preclinical studies, focusing on the unmet medical needs of cancer patients.
Insights from CEO Kris Vaddi
Kris Vaddi, Ph.D., the CEO of Prelude, expressed enthusiasm about sharing these findings. He highlighted the importance of continuing to advance their groundbreaking projects, which are aimed at providing novel therapeutic approaches for patients facing challenging cancer diagnoses. During the symposium, the company will not only provide updates on their Phase 1 trial of PRT3789 but also introduce preclinical data from their new antibody conjugate program.
Innovative Approaches to Cancer Treatment
The data shared at the event reveals a promising strategy: linking a potent dual SMARCA2/4 degrader payload to an antibody that specifically targets tumor cells. This innovative approach has demonstrated the capability to safely induce tumor regressions in animal models, offering a potential replacement for traditional chemotherapy payloads used in antibody-drug conjugates (ADCs). This breakthrough could significantly broaden treatment options for patients, particularly those with SMARCA4 mutant cancers.
Current Progress and Future Trials
The PRT3789, a first-in-class SMARCA2 degrader, is currently in Phase 1 clinical trials specifically for SMARCA4 mutant cancer patients. According to the latest updates, patient enrollment is proceeding well. Prelude anticipates concluding the dose escalation phase of the trial by the end of the year and aims to establish a biologically active dose for future studies. This strategic direction is crucial for supporting future discussions with regulatory authorities regarding further developments.
Key Abstracts and Sessions
The abstracts to be presented at the symposium are particularly noteworthy:
- First Clinical Results from a Phase 1 Trial of PRT3789: This session will occur in Plenary Session #3 at Room 111 + 112 on October 24 from 10:00 AM – 10:12 AM (CEST).
- Discovery of Precision Antibody Drug Conjugates: This poster will be displayed at the Antibody Drug Conjugates session, Abstract #167, on October 24 from 9:00 AM – 5:30 PM (CEST).
- The Selective SMARCA2 Degrader’s Impact: This presentation, focusing on the synergy between PRT3789 and standard chemotherapy, will be featured in the Combination Therapies session, Abstract #220, during the same poster session.
About Prelude Therapeutics
Prelude Therapeutics is a leader in the precision oncology field, dedicated to the development of cutting-edge medicines tailored to meet the high unmet medical needs of cancer patients. The company's extensive pipeline includes promising drug candidates like highly selective SMARCA2 degraders and a state-of-the-art CDK9 inhibitor. Their commitment to advancing targeted protein degradation techniques has positioned them as innovators in the field, poised to redefine treatment paradigms for various cancers.
Investing in the Future
Prelude Therapeutics is not just focused on the present—their visionary approach integrates rigorous research to discover and create next-generation therapies, ensuring they cater to the evolving needs of cancer care. With their eye on collaboration, they are actively pursuing partnerships to expand their reach and streamline the development of precision ADCs.
Frequently Asked Questions
What are the main focus areas for Prelude Therapeutics at the symposium?
Prelude Therapeutics will focus on presenting their SMARCA Degrader Programs and sharing both clinical and preclinical insights from their innovative projects.
When is Prelude Therapeutics scheduled to present at the symposium?
The presentations will occur during the symposium from October 23-25, with specific sessions scheduled throughout those days.
What is PRT3789?
PRT3789 is a first-in-class SMARCA2 degrader currently in Phase 1 clinical trials targeting patients with SMARCA4 mutations.
How does Prelude plan to advance its clinical trials?
Prelude is on track to conclude dose escalation for PRT3789 by the end of the year, intending to establish a biologically active dose for subsequent trials.
What is Prelude’s mission regarding cancer therapies?
Prelude Therapeutics aims to provide innovative, targeted solutions for cancer care, continuing to prioritize unmet medical needs within the oncology space.
